Lupus Nephritis study: Vonsetamig vs Odronextamab
Official title Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis
ClinicalTrials.gov ID: NCT06975787
What this study is testing
What is Vonsetamig?
An investigational drug being studied as a potential treatment for Lupus Nephritis (LN).
Also referred to as REGN5459.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study is testing whether the bispecific antibody drugs are safe and well tolerated in people with lupus nephritis.
- Who it's for
- You may be able to join if you are an adult with lupus nephritis and meet the study’s health criteria.
- What's involved
- You will receive the study drug and have blood tests and check‑ins to monitor side effects and drug levels. The visits are short and scheduled by the study team.
- Time commitment
- The study lasts several weeks, with a few visits for drug administration and follow‑up blood tests.
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 60
You may be able to join if
- Key General
- Diagnosis of Systemic Lupus Erythematosus (SLE) and LN, as described in the protocol
- Participant must have refractory or relapsed disease, as described in the protocol Key General
You likely can't join if
- History of or active severe or unstable lupus-associated neuropsychiatric disease that is likely to require acute or emergent medical treatment or...
- Active overlap syndrome with mixed connective tissue disease or systemic sclerosis within 12 months prior to screening or during screening
- Catastrophic or severe antiphospholipid syndrome within 12 months prior to screening or during screening NOTE: Other protocol defined...
The study team makes the final eligibility decision.
Where it is enrolling
- San Francisco, California, United States
- Gainesville, Florida, United States
- Rochester, Minnesota, United States
- Houston, Texas, United States
- Bordeaux, New Aquitaine, France
- Regensburg, Bavaria, Germany
- Mainz, Germany
- Anyang-si, Gyeonggi-do, South Korea
- Seoul, South Korea
- Seville, Andalusia, Spain
- Pamplona, Navarre, Spain
- Madrid, Spain
- Málaga, Spain
- Changhua, Taiwan
- Taichung, Taiwan
- Taipei, Taiwan
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 60 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at San Francisco, California, United States; Gainesville, Florida, United States; Rochester, Minnesota, United States; Houston, Texas, United States; Bordeaux, New Aquitaine, France; Regensburg, Bavaria, Germany and 10 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.